New Alzheimer’s drug KCL-286 targets DNA damage and inflammation

Researchers have reported early findings for an experimental Alzheimer’s medicine called KCL-286, as reported by ScienceDaily. In a mouse model of the disease, the compound showed promising effects. Rather than targeting mainly the toxic protein clumps that most treatments aim at, it acts on other processes that may start well before the illness becomes advanced.

In these animals, KCL-286 mended broken DNA strands and lowered inflammation in the brain. Both problems can surface early on, so they may be useful points of attack for treatments meant to hold back the illness. The team described the drug as a possible disease-modifying option, not merely a way to manage symptoms.

A notable strength is that KCL-286 has already passed Phase 1 testing for human safety and tolerability during earlier development. Professor Jonathan Corcoran of King’s College London said this could sharply shorten the usual multi-year route for new medicines. Still, whether the drug works against Alzheimer’s in people is unknown at this stage.

Why Alzheimer’s is hard to treat

The disease is driven by many linked changes in the brain, which makes drug design difficult. Two hallmarks are clumps of amyloid-beta that gather as sticky deposits between neurons, and tau protein that twists into tangles within cells. Together these disturb how brain cells communicate and are tied to neurons gradually dying off.

Much of past work has concentrated on these two proteins. Drugs that clear amyloid-beta have produced small but detectable gains in patients. Yet they leave many other biological mechanisms untouched, so scientists are now examining DNA harm and brain inflammation too.

The vitamin A connection

KCL-286 acts by switching on one particular protein within the retinoic acid route. That route belongs to the body’s system for handling vitamin A. The vitamin supports eyesight, but it also contributes to cell growth, control of gene activity and the functioning of the nervous system.

Earlier rat studies linked faults in this route to the build-up of amyloid-beta clumps, which look like a key sign of Alzheimer’s. That suggests the pathway could matter for the disease. Before this study, KCL-286 had also shown it could help fix serious DNA breaks in research on neuropathic pain, a form of pain arising from nerve damage. That result prompted the team to ask whether the same effect might address DNA harm seen in Alzheimer’s.

The same team at King’s College London had earlier mapped biological pathways that acute spinal cord injury and Alzheimer’s have in common. Because the conditions share some mechanisms, they reasoned that a drug aimed at spinal injury could also ease certain Alzheimer’s-related changes in neurons.

What comes next

The Alzheimer’s results are still at the preclinical stage. Further laboratory work and human trials are required before anyone can say whether the compound slows the disease or improves patient outcomes. Natasha Hill, one of the paper’s first authors, said that several aspects of the illness need to be addressed together to build a useful treatment.

Because it is a small molecule that can be swallowed, it could be easier to give than therapies delivered by injection or drip. For the moment, though, it remains an open research question rather than an available treatment.

Frequently asked questions

Sources

• ScienceDaily: Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation

This article was written with the help of AI from reports by the outlets listed above. See our Editorial Policy. Spotted a mistake? Tell us.